This trial is evaluating whether Stereotactic Body Radiotherapy/SBRT will improve 1 primary outcome and 1 secondary outcome in patients with Breast Cancer. Measurement will happen over the course of Up to 2 years.
This trial requires 142 total participants across 2 different treatment groups
This trial involves 2 different treatments. Stereotactic Body Radiotherapy/SBRT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The breast is surrounded by adipocytes and it is possible that the secretion by these cells, both in vitro and in vivo, could cause insulin resistance inducing the onset of insulin-like growth-factor 1 expression, thus the upregulation of growth and survival factors. On the other hand, there is growing evidence that the up-regulation of growth factors in the tumor could be involved as a new mechanism of drug resistance, that lead to the failure of therapy, or a mechanism for metastasis at the primary tumor site.
There are few signs or symptoms of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in the early stages of the disease. Most signs and symptoms of breast cancer are caused by other medical conditions. However, there are a few non-specific signs and symptoms that are commonly associated with breast cancer. These include: a lump or a lump on the breast, swollen lymph nodes, and nipple discharge. Diagnosing breast cancer can be difficult considering the heterogeneity of the presentation of this disease. A complete medical history, an assessment of symptoms, and breast exams are recommended for diagnosing early stage breast cancer, especially lumpectomy.
Recent findings show that after 5 years of follow-up, a significant fraction of the patients (17.1%) had died of breast cancer (95% confidence interval (CI), 10.8-25.8: P=0.027). Five-year survival estimates ranged from 72.3% to 94.2%, with a median survival time of 71.5 months. The five-year cause-specific survival rate was 89.7% (95% CI, 81.1-97.3). There was a significant time-dependent increase in survival rates that was not statistically significant in univariated analyses (P=0.
Breast cancer is a common cancer that affects people of all ages in all parts of the world. It is also the most devastating form of cancer due to its high fatality rate. Many people do not become aware of breast cancer risks until it does occur. As the global incidence of breast cancers is rising, so does its potential of metastasis and fatality rates.
Most common cancers and treatments included surgery, chemotherapy, hormonal treatments, radiation, and targeted therapies. However, some cancers and treatments required multidrug therapies. There is a significant lack of knowledge regarding treatment for many sub-groups such as older and those who have diabetes.
The American Cancer Society estimates that more than two million women in the United States will be diagnosed with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in the years ahead.
The improvement in quality of life seen from SBRT was independent of baseline scores (suggesting that it was not simply a case of regression toward the mean and not any specific effect on QOL). The SBRT treatment in our study was not found to increase QOL.
Stereotactic body radiotherapy is a therapeutic option in the treatment of advanced breast cancer, which is associated with high tumor control and a reduction (by 30%) in axillary nodal disease. The potential advantages of the SBRT are the minimal invasiveness, the very rapid reduction of pain when compared to that seen with traditional radical mastectomy with axillary dissection, and a preservation of most of the axillary lymph nodes.
Breast cancer patients who wish to participate in a new clinical trial should consider the factors and goals listed in the article. Those who wish to participate in a clinical trial should consider clinical trial participation as a potential tool for improving overall breast cancer survival.
There is no consistent agreement in the literature about what the prognosis is after treatment for breast cancer. We demonstrate that the prognosis is dependent on factors like stage of the disease, the presence and extent of metastatic disease, and the age of the patient. Furthermore, we find that after a median interval of 11 years, the survival rate seems to be around 92.6% when adjusted for age and stage of the disease.
I would argue that stereotactic body radiotherapy is not frequently used to target the primary masses of breast cancer because of a number of challenges associated with achieving a thorough and precise target. Even when the primary breast cancer is not the only location, I frequently use this technique for treating additional peripheral masses of breast cancer. These distant metastases may include bone alone or bone with visceral disease elsewhere in the chest wall. The goal here is to apply this technology to treat these extra tumors so that patients who were previously ineligible to have surgery can now proceed to have surgical resection of these extra tumors.
The mean age is 51.1 for breast cancers diagnosed in women over 50. It is 49 for diagnosed in women under 50. The number of women diagnosed with breast cancer increases from 47 million in 1995 to 65 million in 2012; the percentage of women diagnosed with breast cancer has not changed much. There are around 250,000 new cases of breast cancer diagnosed each year and about 10,000 women die from breast cancer.\n